glp 1 drugs and parkinson's disease GLP-1 does not slow progression in phase 3 study Glucagon-like peptide-1 - Wikipedia
Description
13 Regarding the application of GLP-1RAs in MASLD, current understanding suggests they can serve as additional pharmaceutical options in lifestyle management for patients with complications like obesity and T2DM
95% CI 0.16 to 0.42
doi: 10.1186/1475-2891-11-34
Theres no proof Ozempic affects your vision
Obesity, metabolic syndrome, and cardiovascular disease
Ghrelin is a novel regulator of GLP-1 secretion
